ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Arguably the most celebrated example of this has been the use of imatinib, a small molecule inhibitor of the ABL1 tyrosine kinase, to target the fusion protein product of the BCR-ABL translocation seen in chronic myeloid leukaemia [15].